Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer-Reference-Cited by-同舟云学术

Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer

Published:2020-02-04 Issue:2 Volume:180 Page:331-341
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Shibayama Tomoko^ORCID,Low Siew-Kee,Ono Makiko,Kobayashi Takayuki,Kobayashi Kokoro,Fukada Ippei,Ito Yoshinori,Ueno Takayuki,Ohno Shinji,Nakamura Yusuke,Takahashi Shunji

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-019-05512-5.pdf

Reference34 articles.

1. O'Shaughnessy J (2005) Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10(Suppl 3):20–29. https://doi.org/10.1634/theoncologist.10-90003-20

2. Toss A, Cristofanilli M (2015) Molecular characterization and targeted therapeutic approaches in breast cancer. Breast Cancer Res 17:60. https://doi.org/10.1186/s13058-015-0560-9

3. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jaenicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Chaudri-Ross H, Lang R, Wyld P, Bhatnagar A (2003) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21(11):2101–2109. https://doi.org/10.1200/JCO.2003.04.194

4. Johnston SR, Kilburn LS, Ellis P, Dodwell D, Cameron D, Hayward L, Im YH, Braybrooke JP, Brunt AM, Cheung KL, Jyothirmayi R, Robinson A, Wardley AM, Wheatley D, Howell A, Coombes G, Sergenson N, Sin HJ, Folkerd E, Dowsett M, Bliss JM, So FEAi (2013) Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol 14(10):989–998. https://doi.org/10.1016/S1470-2045(13)70322-X

5. Hortobagyi GN (1998) Treatment of breast cancer. N Engl J Med 339(14):974–984. https://doi.org/10.1056/NEJM199810013391407

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Variant allele frequency in circulating tumor DNA correlated with tumor disease burden and predicted outcomes in patients with advanced breast cancer;Breast Cancer Research and Treatment;2024-01-06

2. Machine learning-based somatic variant calling in cell-free DNA of metastatic breast cancer patients using large NGS panels;Scientific Reports;2023-06-27

3. Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer;Breast Cancer Research and Treatment;2023-06-21

4. Machine learning-based somatic variant calling in cell-free DNA of metastatic breast cancer patients using large NGS panels;2023-04-06

5. Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer;Cancers;2023-03-28